Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Carboplatin followed by EBV-specific CTLs in EBV-positive NPC
NCT00690872Phase 2Unknown
- Sponsor
- National Cancer Centre Singapore
- Start
- Jul 2008
- Primary completion
- Dec 2014
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous Epstein-Barr virus-specific cytotoxic T lymphocytes in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Centre Singapore. Primary endpoint: Progression-Free Survival 1. Status: unknown.
02
Drugs
autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00690872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00690872.